12:00 AM
 | 
Jan 20, 2014
 |  BC Week In Review  |  Company News  |  Deals

Galena Biopharma, Mills Pharmaceuticals deal

Galena acquired Mills Pharmaceuticals for about $1.6 million cash up front. Galena gains exclusive, worldwide rights to anagrelide CR ( GALE-401), a controlled-release formulation of generic anti-platelet therapy anagrelide. Former Mills shareholders are eligible to receive 2 million Galena...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >